Our Solutions
The Pain Cloud® B2B platform, created by EptivA Therapeutics, uses the first precision medicine approach to pain, creating more effective treatments, increasing clinical success and reducing costs.
Our approach to research and our Pain Landscape® database allows us to link research targets to disease and significantly de-risk R&D.
Traditional clinical research is based on a relatively small number of pain conditions. However, there are hundreds of conditions associated with pain which could provide more optimal patient groups for analgesic targets.
Our Personalized Analgesics® bioinformatic approach creates thousands of nodes of data via novel human-focused network biology, linked to our proprietary Pain Landscape®.
Technology
Our platform technology has been validated with a wide variety of mechanisms, from established medicines to novel research targets, as well as through a research collaboration with Bayer Pharmaceuticals.
Targets examined through our methodology include:
- CGRP (clinically established target)
- TRPV3 (pre-clinically established target)
- GPR18 (orphan GPCR)
- SV2a (pre-clinical false positive)
- FAAH (pre-clinical false positive)
Applying our technology to CGRP established multiple disease associations also identified the strongest association with migraines with associations with various other novel pain conditions.
1
Network biology principles linked to open access ‘large-data’ for unbiased ‘omic’ enrichment
(click image to enlarge)
2
Adapted, and integrated with Pain Landscape® into a novel, patented in-silico method
(click image to enlarge)
Methodology Examples
(click the arrows to scroll through)
Results Summary Examples
(click the arrows to scroll through)
Our partnership with Infopoly Ltd.
By partnering with digital technology experts Infopoly Ltd., Pain Cloud® has become an automated platform with the development of a back-end tech stack via integrated novel software.
The network biology algorithm can now be operated, automatically accessing huge data sets from high-quality molecular databases, providing unbiased analysis linking research targets to optimized disease phenotypes.
The cloud based digitalisation enables rapid and precise results with novel software applications providing proprietary data visualizations.
Working together to transform how pain is treated
Utilise our novel research techonolgy to increase POS of your R&D projects.
Contact us to find out more.